October 28, 2016
Alexion starts phase 3 trials for two ultra-rare diseases
Alexion Pharmaceuticals has announced the initiation of two Phase 3 trials of ALXN1210…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 28, 2016
Sun Pharma closing down Ocular Technologies buy for $40M plus royalties on its Dry Eye Disease drug (Seciera)
Sun Pharma with its subsidiaries agrees to buy 100% of Ocular Technologies
October 28, 2016
Teva IBM join forces on finding new uses for drugs
IBM and Teva Pharmaceutical Industries Ltd., are expanding their global e-Health alliance to focus on the discovery of new treatment …
October 27, 2016
Bayer profit rises to €1,2 B in Q3 2016
The Bayer Group remained on a path of growth in the third quarter of 2016 and took a major step forward…
October 27, 2016
Newly approved drugs push Lilly’s revenues 5% up, but net income went 3% down
The world’s leading drugmaker Eli Lilly saw a decline in net income for the third…
October 27, 2016
Vertex starts studies for cystic fibrosis treatment
Vertex Pharmaceuticals has announced the planned initiation of two Phase 2 studies to evaluate the next-generation correctors…
October 27, 2016
Allergan to close down buying Motus, relamorelin goes to Phase 3 tests
Allergan on Thursday announced the results of Phase 2b study of the new gastroparesis…
October 27, 2016
Shire spirited up by its antiviral agent (Maribavir) Phase 2 trial results
Shire’s antiviral agent maribavir, studied in the Phase2 trial, has cleared any detectable levels of cytomegalovirus…
October 27, 2016
Allergan: changes to board leadership
Allergan has announced changes to leadership roles within its board of directors.
October 27, 2016
NIH:Gene therapy shows promise for treating Niemann-Pick disease type C1
National Institutes of Health researchers have demonstrated in mice that gene therapy may be the best method for…